Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin alpha-E (also known as CD103 or ITGAE) is a transmembrane glycoprotein that non-covalently pairs with the integrin beta-7 subunit to form the heterodimeric integrin alpha-E/beta-7. This integrin is predominantly expressed on intraepithelial lymphocytes (IELs), mucosal T cells, and subsets of dendritic cells. Its primary ligand is E-cadherin, an adhesion molecule constitutively expressed on epithelial cells. The interaction between integrin alpha-E/beta-7 and E-cadherin is crucial for the homing, retention, and positioning of lymphocytes within mucosal and epithelial tissues, such as the gut, skin, and lungs.
In disease states, integrin alpha-E plays a dual role. In inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease, it mediates the retention of pathogenic, pro-inflammatory T cells that drive chronic mucosal inflammation. Conversely, in oncology, CD103 is a key marker for tumor-infiltrating lymphocytes (TILs), where its expression correlates with tumor-reactive cytotoxic T cell activity and favorable prognosis. Therapeutic strategies targeting this pathway include monoclonal antibodies like etrolizumab and ABBV-243, which block the beta-7 subunit to disrupt both alpha-E/beta-7 and alpha-4/beta-7 interactions, thereby reducing lymphocyte retention and trafficking in the gut. Additionally, CD103-targeted antibody-drug conjugates (ADCs) and imaging tracers are being explored to selectively deplete pathogenic cells or monitor immune responses in cancer.
Inhibition of integrin-mediated cell adhesion and signaling by blocking the interaction between the integrin alpha-E/beta-7 heterodimer and its ligand E-cadherin, thereby preventing the retention and activation of pro-inflammatory lymphocytes in mucosal tissues.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin alpha-E (ITGAE).